Positive Signs For Valneva’s COVID-19 Vaccine, But Efficacy Data And Orders Still Lacking
After UK Cancelled Order, EU Could Provide Lifeline
Executive Summary
Immunogenicity data from Valneva’s COV-COMPARE study are encouraging, but the inactivated vaccine will need proper efficacy data to gain a toehold in a crowded market.
You may also be interested in...
Finance Watch: 2021 Is Now Two Away From 100 Biopharma IPOs
Public Company Edition: Entrada’s initial public offering grossed $181.5m while Aura raised $75.6m and Biofrontera brought in $18m. Also, AnaptysBio received $250m in Jemperli royalty deal and 4D Molecular Therapeutics grossed $118.8m in a follow-on offering.
UK Terminates COVID-19 Vaccine Deal, But Valneva Can Bounce Back
The UK’s decision has hit Valneva’s share price hard, but its vaccine candidates in Chikungunya and Lyme’s disease should help the firm bounce back.
Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.